The road ahead for uniQure: FDA says more data needed for AMT-130 gene therapy

HDBuzz·Mar 2

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

The FDA has requested more data for uniQure's AMT-130 gene therapy, which is intended to treat Huntington's disease. However, there is uncertainty about the impact of the FDA's decision, with some reports indicating a negative effect on uniQure's stock and others suggesting a positive development. The FDA's request may involve an additional clinical trial for the gene therapy.

Full coverage

What Caused uniQure's Dramatic Stock Plunge

Kavout | AI·1d ago

uniQure: FDA's Latest Stance On Huntington's BLA Sends Stock Soaring (NASDAQ:QURE)

Seeking Alpha·Jun 17

UniQure’s Path for Huntington’s Gene Therapy Clouded by Ethical Questions as Potential Phase 3 Looms

BioSpace·Mar 5

UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy

Fierce Biotech·Mar 2

Fetching the latest headlines…

The road ahead for uniQure: FDA says more data needed for AMT-130 gene therapy

Full coverage

What Caused uniQure's Dramatic Stock Plunge

uniQure: FDA's Latest Stance On Huntington's BLA Sends Stock Soaring (NASDAQ:QURE)

UniQure’s Path for Huntington’s Gene Therapy Clouded by Ethical Questions as Potential Phase 3 Looms

UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy

FDA requests additional clinical trial of Huntington’s gene therapy AMT-130

March 2026: This Month in Huntington’s Disease Research

FDA urges new trial for experimental Huntington's gene therapy AMT-130

New Hope for Huntington's: uniQure's Gene Therapy on Accelerated FDA Path